Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07007273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

StatusRecruiting
PhasePhase 2
Started2025-06-20
View on ClinicalTrials.gov ↗

Amendment history

2026-03-31
Study Status v5
Re-verified, no change to tracked fields
2026-01-26
Study Status, Contacts/Locations v4
Study sites1→3
2026-01-05
2 amendments v2-v3
2 re-verifications since 2025-09-23, no change to tracked fields
2025-07-31
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-07-01→confirmed 2025-06-20
Study sitesdetails revised at 1 of 1 site
2025-05-28
Original filing
This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).
Trial Details
NCT Number NCT07007273
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions Cutaneous Sarcoma
Enrollment 17 participants
Start Date 2025-06-20
Primary Completion 2030-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-01